Caption Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Caption Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-521,600	Closed	-$6.84M	–	1450
2024 Q3	$6.84M	Buy	521,600 +358,300	+219%	+$5.46M	0.11%	225
2024 Q2	$2.3M	Buy	163,300 +154,300	+1,714%	+$2.52M	0.04%	442
2024 Q1	$152K	Buy	+9,000	New	+$134K	﹤0.01%	1028
2022 Q1	–	Sell	-279,500	Closed	-$2.26M	–	1453
2021 Q4	$2.26M	Buy	+279,500	New	+$2.55M	0.03%	743
2021 Q2	–	Sell	-50,000	Closed	-$453K	–	1288
2021 Q1	$453K	Buy	+50,000	New	+$404K	0.01%	830

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Caption Management's AVDL Position: Q1 2026 in Review

Caption Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 536,838 shares — an estimated $11.6M sold.

Caption Management first reported a position in AVDL in Q3 2020 and held it in 16 quarters. The position peaked at $11.6M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Caption Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Caption Management sold 536,838 Avadel Pharmaceuticals shares in Q1 2026, an estimated $11.6M.
Caption Management first reported a position in Avadel Pharmaceuticals in Q3 2020 and held it in 16 quarters.
Caption Management's Avadel Pharmaceuticals position peaked at $11.6M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.